These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 27477525)

  • 21. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
    Beer TM; Miller K; Tombal B; Cella D; Phung D; Holmstrom S; Ivanescu C; Skaltsa K; Naidoo S
    Eur J Cancer; 2017 Dec; 87():21-29. PubMed ID: 29096157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    Sternberg CN; Fizazi K; Saad F; Shore ND; De Giorgi U; Penson DF; Ferreira U; Efstathiou E; Madziarska K; Kolinsky MP; Cubero DIG; Noerby B; Zohren F; Lin X; Modelska K; Sugg J; Steinberg J; Hussain M;
    N Engl J Med; 2020 Jun; 382(23):2197-2206. PubMed ID: 32469184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
    Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
    J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B;
    N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
    Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM
    Eur J Cancer; 2022 Jul; 170():285-295. PubMed ID: 35643841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased survival with enzalutamide in prostate cancer after chemotherapy.
    Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
    N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer-updated results.
    Kimura G; Ueda T
    Jpn J Clin Oncol; 2017 Mar; 47(3):262-264. PubMed ID: 28003320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
    Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
    Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
    Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
    Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
    Armstrong AJ; Lin P; Higano CS; Sternberg CN; Sonpavde G; Tombal B; Templeton AJ; Fizazi K; Phung D; Wong EK; Krivoshik A; Beer TM
    Ann Oncol; 2018 Nov; 29(11):2200-2207. PubMed ID: 30202945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
    Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
    J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of enzalutamide for metastatic castration-resistant prostate cancer.
    Bhattacharya S; Hirmand M; Phung D; van Os S
    Ann N Y Acad Sci; 2015 Nov; 1358():13-27. PubMed ID: 26384731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.